{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:21Z","timestamp":1740144201486,"version":"3.37.3"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Patients with chronic kidney disease (CKD are frequently excluded from coronary artery disease trials. The aim of this assessment was to study the clinical outcomes of polymer-free sirolimus-eluting stent implantations in patients with impaired renal function.<\/jats:p>\n            <jats:p>Large-scale, international, single-armed, multicenter, \u2018all comers\u2019 observational studies (ClinicalTrials.gov Identifier: NCT02629575 and NCT02905214) were used for this post-hoc subgroup analysis to compare the clinical outcomes in patients with normal renal function (NRF) to those with renal insufficiency (CKD, dialysis dependence). The accumulated target lesion revascularization rate was the primary endpoint at 9 to 12 months whereas the accumulated major adverse cardiac event, stent thrombosis (ST) and procedural success rates were part of the secondary endpoints.<\/jats:p>\n            <jats:p>There were 6791 patients with NRF, whereas 369 patients had CKD and 83 patients were dialysis dependent. The target lesion revascularization rate at 9 to 12 months was significantly higher in dialysis patients (2.1% vs 3.3% vs 6.7%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.011). The accumulated major adverse cardiac events rates in the dialysis and in the CKD group were significantly higher as compared to patients with NRF (13.3% vs 4.0%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001; 6.5% vs 4.0%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.024). Finally, ST rates (NRF: 0.7%, CKD: 0.6%, dialysis: 1.3%) were not statistically different between subgroups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.768). All-cause cumulative mortality rates were 3.3% (CKD) and 4.0% (dialysis) respectively.<\/jats:p>\n            <jats:p>Percutaneous coronary interventions with polymer-free, ultra-thin strut sirolimus-eluting stents have comparable revascularization rates in CKD and dialysis dependent patients as compared to percutaneous coronary interventions with other 2nd generation drug-eluting stents. ST and all-cause mortality rates were low as compared to available literature references.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021244","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T18:03:02Z","timestamp":1595008982000},"page":"e21244","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes following polymer-free sirolimus-eluting stent implantations in unselected patients"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5965-8817","authenticated-orcid":false,"given":"Florian","family":"Krackhardt","sequence":"first","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin, Internal Medicine and Cardiology, Campus Virchow"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-4505","authenticated-orcid":false,"given":"Matthias W.","family":"Waliszewski","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin, Internal Medicine and Cardiology, Campus Virchow"},{"name":"Department of Medical Scientific Affairs, Vascular Systems, Aesculap, B. Braun Melsungen AG, Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behrouz","family":"Kherad","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin, Internal Medicine and Cardiology, Campus Virchow"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Barth","sequence":"additional","affiliation":[{"name":"Department of Medical Scientific Affairs, Avitum, B.Braun Melsungen AG, Melsungen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7650-8578","authenticated-orcid":false,"given":"Daniele","family":"Marcelli","sequence":"additional","affiliation":[{"name":"Department of Medical Scientific Affairs, Avitum, B.Braun Melsungen AG, Melsungen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"(Suppl 1)","key":"R3-20230915","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1755-6686.2010.00171.x","article-title":"Clinical epidemiology of cardiovascular disease in chronic kidney disease","volume":"36","author":"Foley","year":"2010","journal-title":"J Ren Care"},{"key":"R4-20230915","first-page":"592","article-title":"Risk factors and underlying cardiovascular diseases in incident ESRD patients","volume":"18","author":"Di Benedetto","year":"2005","journal-title":"J Nephrol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ndt\/15.suppl_5.69","article-title":"Cardiovascular disease in chronic renal failure: the challenge continues","volume":"15","author":"Locatelli","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk, Epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/ki.2015.117","article-title":"High cardiovascular event rates occur within the first weeks of starting hemodialysis","volume":"88","author":"Eckardt","year":"2015","journal-title":"Kidney Int"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jacc.2018.11.044","article-title":"Impact of chronic kidney disease on outcomes of myocardial revascularization in patients with diabetes","volume":"73","author":"Farkouh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.jcin.2016.06.051","article-title":"Chronic kidney disease in the second-generation drug-eluting stent era: pooled analysis of the korean multicenter drug-eluting stent registry","volume":"9","author":"Lee","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"COURAGE trial research group. optimal medical therapy with or without pci for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"SENIOR investigators. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/openhrt-2017-000592","article-title":"Polymer-free sirolimus-eluting stents in a large-scale all-comers population","volume":"4","author":"Krackhardt","year":"2017","journal-title":"Open Heart"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"e19119","DOI":"10.1097\/MD.0000000000019119","article-title":"Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice","volume":"99","author":"Krackhardt","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"e0226606","DOI":"10.1371\/journal.pone.0226606","article-title":"Polymer-free sirolimus-eluting stent use in Europe and Asia: ethnic differences in demographics and clinical outcomes","volume":"15","author":"Krackhardt","year":"2020","journal-title":"PLoS One"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/ccd.27306","article-title":"Propensity score matched all comers population treated with ultra-thin strut bare metal and sirolimus-probucol coated drug-eluting stents of identical stent architecture","volume":"91","author":"Krackhardt","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Joint ESC\/ACCF\/AHA\/WHF task force for universal definition of myocardial infarction, authors\/task force members chairpersons, biomarker subcommittee, ecg subcommittee, imaging subcommittee, classification subcommittee, intervention subcommittee, trials & registries subcommittee, trials & registries subcommittee, trials & registries subcommittee, trials & registries subcommittee, esc committee for practice guidelines (cpg), document reviewers. third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10554-006-9186-4","article-title":"Tortuosity of coronary arteries: an indicator for impaired left ventricular relaxation?","volume":"23","author":"Turgut","year":"2007","journal-title":"Int J Cardiovasc Imaging"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jcin.2016.01.009","article-title":"Randomized trial of polymer-free sirolimus- and probucol-eluting stents versus durable polymer zotarolimus-eluting stents 5-year results of the ISAR-TEST-5 trial JACC Cardiovasc","volume":"9","author":"Kufner","year":"2016","journal-title":"JACC Cardiovasc Interventions"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014\u200aESC\/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the european association of percutaneous cardiovascular interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.amjcard.2017.01.029","article-title":"Comparative efficacy of coronary revascularization procedures for multivessel coronary artery disease in patients with chronic kidney disease","volume":"119","author":"Roberts","year":"2017","journal-title":"Am J Cardiol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2015.06.1334","article-title":"Revascularization in patients with multivessel coronary artery disease and chronic kidney disease: everolimus-eluting stents versus coronary artery bypass graft surgery","volume":"66","author":"Bangalore","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2016.03.033","article-title":"Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial","volume":"212","author":"Crimi","year":"2016","journal-title":"Int J Cardiol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndt\/gfv111","article-title":"Vascular calcification in chronic kidney disease: An update","volume":"31","author":"Schlieper","year":"2016","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"R26-20230915","first-page":"273","article-title":"Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients","volume":"18","author":"Hassani","year":"2006","journal-title":"J Invasive Cadiol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"1753944719826335","DOI":"10.1177\/1753944719826335","article-title":"Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries","volume":"13","author":"Sperling","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/cdt.2019.04.06","article-title":"Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome","volume":"9","author":"Ofori-Asenso","year":"2019","journal-title":"Cardiovasc Diagn Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:29:30Z","timestamp":1694827770000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021244"}},"subtitle":["A descriptive subgroup analysis in patients with renal impairment"],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":28,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021244","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,7,17]]}}}